{"id":36164,"date":"2025-10-29T14:07:19","date_gmt":"2025-10-29T13:07:19","guid":{"rendered":"https:\/\/ggba.swiss\/tubulis-raises-eur-308-million-to-advance-adc-therapies-and-expand-its-clinical-pipeline\/"},"modified":"2025-10-29T14:09:21","modified_gmt":"2025-10-29T13:09:21","slug":"tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/","title":{"rendered":"Tubulis l\u00e8ve EUR 308 millions pour acc\u00e9l\u00e9rer le d\u00e9veloppement de ses th\u00e9rapies ADC"},"content":{"rendered":"\n<p><a href=\"https:\/\/tubulis.com\/\">Tubulis<\/a>, soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans les conjugu\u00e9s anticorps-m\u00e9dicament (ADC), a lev\u00e9 EUR 308 millions dans le cadre d\u2019un financement de s\u00e9rie C, la plus importante lev\u00e9e jamais r\u00e9alis\u00e9e par une biotech priv\u00e9e en Europe et la plus \u00e9lev\u00e9e au monde pour une entreprise ax\u00e9e sur les ADC. Le tour de table a \u00e9t\u00e9 men\u00e9 par <a href=\"https:\/\/www.venrock.com\/\">Venrock Healthcare Capital Partners<\/a>, avec la participation de <a href=\"https:\/\/www.wellington.com\/\">Wellington Management<\/a>, <a href=\"https:\/\/www.ascentacap.com\/\">Ascenta Capital<\/a> et des investisseurs existants, notamment <a href=\"https:\/\/www.nextechinvest.com\/\">Nextech Invest<\/a>, <a href=\"https:\/\/eqtgroup.com\/private-capital\/eqt-life-sciences\">EQT Life Sciences<\/a>, <a href=\"https:\/\/frazierls.com\/\">Frazier Life Sciences<\/a> et <a href=\"https:\/\/www.anderapartners.com\/en\/\">Andera Partners<\/a>.<\/p>\n\n\n\n<p>Bas\u00e9e \u00e0 Munich et d\u00e9sormais implant\u00e9e sur le campus <a href=\"https:\/\/www.biopole.ch\/\">Biop\u00f4le<\/a> de Lausanne, Tubulis d\u00e9veloppe une nouvelle g\u00e9n\u00e9ration d\u2019ADC combinant ciblage th\u00e9rapeutique, stabilit\u00e9 accrue et activit\u00e9 antitumorale prolong\u00e9e. Son principal candidat, TUB-040, cible l\u2019antig\u00e8ne NaPi2b, surexprim\u00e9 dans le cancer de l\u2019ovaire et l\u2019ad\u00e9nocarcinome pulmonaire. Il est actuellement \u00e9valu\u00e9 dans une \u00e9tude clinique de phase I\/IIa (NAPISTAR1-01) et a obtenu la d\u00e9signation Fast Track de la FDA en 2024.<\/p>\n\n\n\n<p>Ce financement permettra d\u2019\u00e9tendre le d\u00e9veloppement de TUB-040 \u00e0 d\u2019autres types de tumeurs et \u00e0 des lignes de traitement plus pr\u00e9coces, tout en soutenant la progression clinique de TUB-030, qui cible l\u2019antig\u00e8ne 5T4, ainsi que de plusieurs programmes pr\u00e9cliniques. Tubulis poursuivra \u00e9galement le d\u00e9veloppement de ses plateformes technologiques propri\u00e9taires afin d\u2019explorer de nouvelles applications th\u00e9rapeutiques en oncologie.<\/p>\n\n\n\n<p>\u00ab Cette lev\u00e9e de fonds historique refl\u00e8te la forte confiance des investisseurs dans Tubulis et le potentiel de rupture de nos plateformes ADC, \u00bb a d\u00e9clar\u00e9 le Dr Dominik Schumacher, CEO et cofondateur. \u00ab Avec TUB-040 en progression clinique et des donn\u00e9es attendues prochainement, nous sommes pr\u00eats \u00e0 \u00e9largir nos programmes de d\u00e9veloppement et \u00e0 apporter des ADC v\u00e9ritablement diff\u00e9renci\u00e9s aux patients. \u00bb<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Un leader europ\u00e9en de l\u2019oncologie de pr\u00e9cision<\/h4>\n\n\n\n<p>Fond\u00e9e en 2019, Tubulis red\u00e9finit la th\u00e9rapie cibl\u00e9e contre le cancer gr\u00e2ce \u00e0 des ADC parfaitement adapt\u00e9s, capables d\u2019assurer une d\u00e9livrance durable sur la tumeur et une activit\u00e9 antitumorale prolong\u00e9e. En alliant l\u2019excellence scientifique allemande \u00e0 l\u2019\u00e9cosyst\u00e8me collaboratif de la Suisse occidentale, l\u2019entreprise renforce la position de l\u2019Europe dans le domaine de l\u2019oncologie de pr\u00e9cision.<\/p>\n\n\n\n<p>Avec ce financement record et sa pr\u00e9sence croissante au Biop\u00f4le, Tubulis s\u2019impose parmi les leaders mondiaux qui fa\u00e7onnent la prochaine g\u00e9n\u00e9ration de conjugu\u00e9s anticorps-m\u00e9dicament pour am\u00e9liorer le pronostic des patients atteints de tumeurs solides.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La soci\u00e9t\u00e9 biopharmaceutique bas\u00e9e \u00e0 Munich et Lausanne r\u00e9alise la plus grande lev\u00e9e de fonds de s\u00e9rie C jamais enregistr\u00e9e en Europe pour acc\u00e9l\u00e9rer le d\u00e9veloppement de conjugu\u00e9s anticorps-m\u00e9dicament de nouvelle g\u00e9n\u00e9ration.<\/p>\n","protected":false},"author":6,"featured_media":36161,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1140,1168],"class_list":["post-36164","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-oncology-fr-2","tag-technology-park-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tubulis l\u00e8ve EUR 308 millions | GGBa<\/title>\n<meta name=\"description\" content=\"Tubulus r\u00e9alise la plus grande lev\u00e9e de fonds enregistr\u00e9e en Europe pour acc\u00e9l\u00e9rer le d\u00e9veloppement de ses conjugu\u00e9s anticorps-m\u00e9dicament.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tubulis l\u00e8ve EUR 308 millions | GGBa\" \/>\n<meta property=\"og:description\" content=\"Tubulus r\u00e9alise la plus grande lev\u00e9e de fonds enregistr\u00e9e en Europe pour acc\u00e9l\u00e9rer le d\u00e9veloppement de ses conjugu\u00e9s anticorps-m\u00e9dicament.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T13:07:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T13:09:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Tubulis l\u00e8ve EUR 308 millions pour acc\u00e9l\u00e9rer le d\u00e9veloppement de ses th\u00e9rapies ADC\",\"datePublished\":\"2025-10-29T13:07:19+00:00\",\"dateModified\":\"2025-10-29T13:09:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/\"},\"wordCount\":449,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Financing\",\"Oncology\",\"Technology Park\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/\",\"name\":\"Tubulis l\u00e8ve EUR 308 millions | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg\",\"datePublished\":\"2025-10-29T13:07:19+00:00\",\"dateModified\":\"2025-10-29T13:09:21+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Tubulus r\u00e9alise la plus grande lev\u00e9e de fonds enregistr\u00e9e en Europe pour acc\u00e9l\u00e9rer le d\u00e9veloppement de ses conjugu\u00e9s anticorps-m\u00e9dicament.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"L\u2019\u00e9quipe de Tubulis sur le campus du Biop\u00f4le \u00e0 Lausanne, lors de l\u2019ouverture de ses bureaux suisses en 2025 d\u00e9di\u00e9s \u00e0 la recherche sur les conjugu\u00e9s anticorps-m\u00e9dicament de nouvelle g\u00e9n\u00e9ration. | \u00a9 Biop\u00f4le\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tubulis l\u00e8ve EUR 308 millions pour acc\u00e9l\u00e9rer le d\u00e9veloppement de ses th\u00e9rapies ADC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tubulis l\u00e8ve EUR 308 millions | GGBa","description":"Tubulus r\u00e9alise la plus grande lev\u00e9e de fonds enregistr\u00e9e en Europe pour acc\u00e9l\u00e9rer le d\u00e9veloppement de ses conjugu\u00e9s anticorps-m\u00e9dicament.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/","og_locale":"fr_FR","og_type":"article","og_title":"Tubulis l\u00e8ve EUR 308 millions | GGBa","og_description":"Tubulus r\u00e9alise la plus grande lev\u00e9e de fonds enregistr\u00e9e en Europe pour acc\u00e9l\u00e9rer le d\u00e9veloppement de ses conjugu\u00e9s anticorps-m\u00e9dicament.","og_url":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-10-29T13:07:19+00:00","article_modified_time":"2025-10-29T13:09:21+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Tubulis l\u00e8ve EUR 308 millions pour acc\u00e9l\u00e9rer le d\u00e9veloppement de ses th\u00e9rapies ADC","datePublished":"2025-10-29T13:07:19+00:00","dateModified":"2025-10-29T13:09:21+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/"},"wordCount":449,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg","keywords":["Biotech","Financing","Oncology","Technology Park"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/","url":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/","name":"Tubulis l\u00e8ve EUR 308 millions | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg","datePublished":"2025-10-29T13:07:19+00:00","dateModified":"2025-10-29T13:09:21+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Tubulus r\u00e9alise la plus grande lev\u00e9e de fonds enregistr\u00e9e en Europe pour acc\u00e9l\u00e9rer le d\u00e9veloppement de ses conjugu\u00e9s anticorps-m\u00e9dicament.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/10\/Tubulis-Biopole-2025-1180x811-1.jpg","width":1180,"height":811,"caption":"L\u2019\u00e9quipe de Tubulis sur le campus du Biop\u00f4le \u00e0 Lausanne, lors de l\u2019ouverture de ses bureaux suisses en 2025 d\u00e9di\u00e9s \u00e0 la recherche sur les conjugu\u00e9s anticorps-m\u00e9dicament de nouvelle g\u00e9n\u00e9ration. | \u00a9 Biop\u00f4le"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/tubulis-leve-eur-308-millions-pour-accelerer-le-developpement-de-ses-therapies-adc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Tubulis l\u00e8ve EUR 308 millions pour acc\u00e9l\u00e9rer le d\u00e9veloppement de ses th\u00e9rapies ADC"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/36164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=36164"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/36164\/revisions"}],"predecessor-version":[{"id":36166,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/36164\/revisions\/36166"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/36161"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=36164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=36164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=36164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}